N-Acetyl-Calicheamicin
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | New Products |
| Catalog number | BBF-05733 |
| CAS | 108212-76-6 |
| Molecular Weight | 1410.38 |
| Molecular Formula | C57H76IN3O22S4 |
| Purity | 95% |
Ordering Information
| Catalog Number | Size | Price | Stock | Quantity |
|---|---|---|---|---|
| BBF-05733 | 1 mg | $1999 | In stock |
Online Inquiry
Add to cartDescription
N-Acetyl-Calicheamicin is a potent enediyne antitumor antibiotic that could be a potential cytotoxic DNA-binding agent in antibody-drug-conjugation (ADC). Calicheamicin is a naturally occurring hydrophobic enediyne antibiotic that was isolated from the actinomycete Micromonospora echinospora calichensis.
Specification
| Synonyms | N-Acetyl-Calicheamicin γ1; N-Acetyl-Calicheamicin γ; N-Acetyl-Calicheamicin; N-Acetyl-γ-calicheamicin |
| Shelf Life | As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly |
| Storage | Store at 2-8°C for short term (days to weeks) or -20°C for long term (months to years) |
| IUPAC Name | S-[(2R,3S,4S,6S)-6-[[(2R,3S,4S,5R,6R)-5-[(2S,4S,5S)-5-[acetyl(ethyl)amino]-4-methoxyoxan-2-yl]oxy-4-hydroxy-6-[[(2S,5Z,9R,13E)-9-hydroxy-12-(methoxycarbonylamino)-13-[2-(methyltrisulfanyl)ethylidene]-11-oxo-2-bicyclo[7.3.1]trideca-1(12),5-dien-3,7-diynyl]oxy]-2-methyloxan-3-yl]amino]oxy-4-hydroxy-2-methyloxan-3-yl] 4-[(2S,3R,4R,5S,6S)-3,5-dihydroxy-4-methoxy-6-methyloxan-2-yl]oxy-5-iodo-2,3-dimethoxy-6-methylbenzenecarbothioate |
| Canonical SMILES | CCN(C1COC(CC1OC)OC2C(C(C(OC2OC3C#CC=CC#CC4(CC(=O)C(=C3C4=CCSSSC)NC(=O)OC)O)C)NOC5CC(C(C(O5)C)SC(=O)C6=C(C(=C(C(=C6OC)OC)OC7C(C(C(C(O7)C)O)OC)O)I)C)O)O)C(=O)C |
| InChI | InChI=1S/C57H76IN3O22S4/c1-13-61(30(6)62)32-25-76-37(23-36(32)71-7)81-50-45(66)42(27(3)78-55(50)80-35-18-16-14-15-17-20-57(70)24-34(64)43(59-56(69)75-11)40(35)31(57)19-21-85-87-84-12)60-83-38-22-33(63)52(29(5)77-38)86-53(68)39-26(2)41(58)48(51(74-10)47(39)72-8)82-54-46(67)49(73-9)44(65)28(4)79-54/h14-15,19,27-29,32-33,35-38,42,44-46,49-50,52,54-55,60,63,65-67,70H,13,21-25H2,1-12H3,(H,59,69)/b15-14-,31-19+/t27-,28+,29-,32+,33+,35+,36+,37+,38+,42-,44+,45+,46-,49-,50-,52-,54+,55+,57+/m1/s1 |
| InChI Key | WPDOZYZAJKUVRZ-IOCYQWGVSA-N |
Properties
| Appearance | Solid Powder |
| Antibiotic Activity Spectrum | Neoplastics (Tumor) |
| Density | 1.6±0.1 g/cm3 |
| Solubility | Soluble in DMSO (10 mm) |
Reference Reading
1.Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia.
Stasi R;Evangelista ML;Buccisano F;Venditti A;Amadori S Cancer Treat Rev. 2008 Feb;34(1):49-60. Epub 2007 Oct 17.
Gemtuzumab ozogamicin (GO) is a chemotherapeutic agent that consists of a humanized anti-CD33 antibody (hP67.6) linked to N-acetyl-calicheamicin 1,2-dimethyl hydrazine dichloride, a potent enediyne antitumor antibiotic. GO was approved conditionally by the Federal Drug Administration in May 2000 as single-agent therapy for first recurrence of acute myeloid leukemia (AML) in patients over the age of 60 years who are unfit for conventional cytotoxic therapy. In this setting, it produces a complete response (CR) rate of 13%, with another 13% achieving CR with inadequate platelet recovery (CRp). The most common adverse effects associated with GO are infusion-related reactions and myelosuppression. GO monotherapy at the dose of 9 mg/m(2) is complicated with hepatic veno-occlusive disease in approximately 5% of cases, particularly prior to or following stem cell transplantation. Attenuated doses of GO or fractionated doses appear to be equally effective and better tolerated. GO has shown remarkable activity in acute promyelocytic leukemia, particularly for the elimination of minimal residual disease. Combinations of GO with chemotherapy as induction or post-remission therapy are promising, and phase III trials are ongoing.
Recommended Products
| BBF-00693 | Ansamitocin P-3 | Inquiry |
| BBF-01732 | Mevastatin | Inquiry |
| BBF-01825 | Loganin | Inquiry |
| BBF-05734 | Irofulven | Inquiry |
| BBF-05806 | Zeaxanthin | Inquiry |
| BBF-02582 | Polyporenic acid C | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
